Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
A.J. Bergmann - Chief Financial Officer
Linda Marbán - Chief Executive Officer
Conference Call Participants
Ted Tenthoff - Piper Sandler
Leland Gershell - Oppenheimer
Rick Miller - Cantor Fitzgerald
Aydin Huseynov - Ladenburg
Operator
Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2024 Financial Results and Corporate Update Call. At this time, all participant lines are in a listen-only mode. Following the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Wednesday, November 13, 2024.
I would now like to turn the conference over to our host, Mr. A.J. Bergmann, Capricor's Chief Financial Officer, for the forward-looking statement. Please go ahead.
A.J. Bergmann
Thank you and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, revenue and reimbursement estimates, projected terms of definitive agreements, manufacturing capabilities, potential milestone payments, our financial position and our possible uses of existing cash and investment resources.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements and we disclaim any obligation to update such statements.
With that, I'll turn the call over to Linda Marbán, CEO.
Linda Marbán
Thanks, A.J. Good afternoon, everyone and thank you for joining today's third quarter conference call. I am extremely proud of the progress we have made in the last quarter. As you know, we have been working to develop deramiocel, formerly known as CAP-1002 for the treatment of DMD for the last 8 years. We have shown in multiple clinical trials, the solutory benefits of deramiocel in attenuating the consequences of the skeletal muscle myopathy and improving the cardiomyopathy associated with this devastating disease. We have consistently presented the data as it has become available to the FDA and the data has shown clinically meaningful as well as statistically significant improvements. Based on the strength of the data as well as the large unmet medical need of the cardiac implications, we have decided after conferring with the FDA to file a BLA for full approval for the cardiomyopathy associated with DMD.